Total Payments
$697,284
2024 Payments
$219,680
Companies
20
Transactions
732
Medicare Patients
148
Medicare Billing
$18,511
Payment Breakdown by Category
Other$590,836 (84.7%)
Travel$74,718 (10.7%)
Food & Beverage$16,929 (2.4%)
Consulting$14,645 (2.1%)
Education$156.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $543,546 | 154 | 78.0% |
| Travel and Lodging | $74,718 | 289 | 10.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $28,750 | 8 | 4.1% |
| Honoraria | $17,140 | 11 | 2.5% |
| Food and Beverage | $16,929 | 260 | 2.4% |
| Consulting Fee | $14,645 | 6 | 2.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,400 | 1 | 0.2% |
| Education | $156.29 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | $226,509 | 204 | $0 (2024) |
| Gilead Sciences, Inc. | $161,874 | 197 | $0 (2023) |
| Madrigal Pharmaceuticals | $108,336 | 94 | $0 (2024) |
| ABBVIE INC. | $87,064 | 100 | $0 (2022) |
| Intercept Pharmaceuticals, Inc. | $50,793 | 56 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $44,630 | 42 | $0 (2018) |
| Shionogi Inc | $7,806 | 7 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $5,346 | 7 | $0 (2024) |
| Dova Pharmaceuticals | $3,875 | 2 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $229.34 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $219,680 | 193 | Madrigal Pharmaceuticals ($108,336) |
| 2023 | $128,860 | 125 | Mallinckrodt Hospital Products Inc. ($119,292) |
| 2022 | $18,699 | 44 | Gilead Sciences, Inc. ($17,134) |
| 2021 | $35,472 | 30 | Gilead Sciences, Inc. ($16,900) |
| 2020 | $22,936 | 19 | Gilead Sciences, Inc. ($16,922) |
| 2019 | $66,201 | 62 | AbbVie, Inc. ($35,115) |
| 2018 | $42,545 | 45 | Gilead Sciences, Inc. ($19,255) |
| 2017 | $162,892 | 214 | Gilead Sciences Inc ($59,774) |
All Payment Transactions
732 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/13/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,883.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $593.01 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $112.53 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $190.30 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $123.72 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $50.92 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $25.52 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,583.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,115.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $1,006.73 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $513.48 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $269.48 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $210.68 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $159.49 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $128.87 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $124.18 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: LIVER DISEASE | ||||||
| 11/22/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/22/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $701.95 | General |
| Category: LIVER DISEASE | ||||||
| 11/22/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $331.98 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 23 | 26 | $7,231 | $1,967 |
| 2022 | 6 | 89 | 138 | $33,660 | $13,158 |
| 2021 | 3 | 36 | 41 | $10,259 | $3,387 |
Total Patients
148
Total Services
205
Medicare Billing
$18,511
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 13 | $4,631 | $1,329 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 13 | $2,600 | $637.46 | 24.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 60 | $13,260 | $5,197 | 39.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $6,570 | $2,621 | 39.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 18 | $5,238 | $1,938 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 13 | $3,692 | $1,453 | 39.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 17 | $3,400 | $1,351 | 39.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 12 | $1,500 | $597.48 | 39.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $5,992 | $1,643 | 27.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 13 | $1,547 | $945.72 | 61.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 16 | $2,720 | $797.70 | 29.3% |
About Dr. Santiago Munoz, MD
Dr. Santiago Munoz, MD is a Transplant Hepatology healthcare provider based in Toms River, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578531190.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Santiago Munoz, MD has received a total of $697,284 in payments from pharmaceutical and medical device companies, with $219,680 received in 2024. These payments were reported across 732 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($543,546).
As a Medicare-enrolled provider, Munoz has provided services to 148 Medicare beneficiaries, totaling 205 services with total Medicare billing of $18,511. Data is available for 3 years (2021–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Transplant Hepatology
- Other Specialties Transplant Hepatology
- Location Toms River, NJ
- Active Since 03/09/2006
- Last Updated 05/15/2023
- Taxonomy Code 207RT0003X
- Entity Type Individual
- NPI Number 1578531190
Products in Payments
- TERLIVAZ (Drug) $226,217
- Epclusa (Drug) $122,970
- REZDIFFRA (Drug) $108,234
- Mavyret (Drug) $48,996
- ZEPATIER (Drug) $44,630
- OCA (Drug) $38,659
- MAVYRET (Drug) $14,033
- Viekira (Drug) $12,978
- Vemlidy (Drug) $10,969
- OCALIVA (Drug) $10,733
- Mulpleta (Drug) $7,806
- Vosevi (Drug) $5,707
- Bylvay (Drug) $5,216
- Doptelet (Drug) $3,875
- XIFAXAN (Drug) $247.59
- IQIRVO (Drug) $166.19
- Livmarli (Drug) $133.36
- THERASPHERE - BIO (Device) $129.85
- Strensiq (Drug) $124.00
- RESMETIROM (Drug) $102.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.